Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Tuesday asked the U.S. Food and Drug Administration to ban compounding ...

Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...

Novo Nordisk has been slowly increasing production capacity of its highly coveted weight loss drugs. As a result, thousands of people have began treatment per week. Wegovy has been FDA-approved ...

Novo Nordisk A/S (NVO) investors who had anticipated that the stock could continue outperforming the market were likely disappointed. Accordingly, NVO has underperformed the S&P 500 (SPX ...

Novo Nordisk (NVO) (OTCPK:NONOF) ADRs traded higher in the premarket on Wednesday after the Danish drugmaker released full ...

Bernie Sanders called "outrageously high" prices for the drugs. Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee ...

The chief executive of the drugmaker Novo Nordisk, Lars Fruergaard Jørgensen, is scheduled to face tough questions Tuesday on Capitol Hill about the high costs of the company’s widely popular w ...

Bernstein analyst Florent Cespedes maintained a Sell rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK560.00. The company’s shares closed last Friday at ...

Catalent, a leading contract drug manufacturer, issued an open letter on Monday to reassure customers that a proposed $16.5 billion deal — in which it would be acquired by Novo Nordisk’s ...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity ...

Novo Nordisk A/S (NYSE:NVO) CEO Lars Fruergaard Jørgensen has defended the high U.S. prices of the company’s blockbuster ...